Gate Neurosciences
PrivateLast Round
M&A
May 27, 2025
Total Funding Raised
$58.9M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Gate Neurosciences operates in Healthcare & Life Sciences and is based in Indianapolis, Indiana. Its latest recorded funding round was a Convertible Debt round in December 2024.
Gate Neurosciences is a biotechnology company that develops precision medicines to treat central nervous system disorders by enhancing synaptic function and neuroplasticity.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials, Mental Health
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Gate Neurosciences Comparables
Compare Gate Neurosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Otsuka Holdings | 81% | |
| Delix Therapeutics | 81% | |
| Spinogenix, Inc. | 78% |
For institutional investors. Book with your work email.
Gate Neurosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | May 27, 2025 | ||||
| Convertible Debt | Dec 31, 2024 | ||||
| Convertible Debt | Sep 30, 2022 | ||||
| Convertible Debt | Nov 24, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Gate Neurosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioCrossroads | Convertible Debt, Seed |
| Luson BioVentures | Convertible Debt, M&A |
| Innoviva | Convertible Debt, M&A |
| Catalio Capital Management | M&A |
| M Capital | M&A |
| PagodaTree Partners | M&A |
| Tenmile | M&A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 1, 2026
Open roles increased to 2, 3x the trailing average.
- Sep 1, 2026
Open roles increased by 2, representing 200% of headcount.
For institutional investors. Book with your work email.
Gate Neurosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Gate Neurosciences's valuation, stock price, and market status.
Is Gate Neurosciences a public or private company?
Gate Neurosciences is a private company.
What is the current stock price of Gate Neurosciences?
Gate Neurosciences is a private company, so its shares have no public market price. Caplight tracks Gate Neurosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Gate Neurosciences worth (valuation)?
Valuation information for Gate Neurosciences is not publicly available.
Can I buy Gate Neurosciences stock?
Gate Neurosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Gate Neurosciences's last funding round?
Gate Neurosciences's most recent funding round was M&A on May 27, 2025.
Who are the main investors in Gate Neurosciences?
Key investors in Gate Neurosciences include Innoviva, Catalio Capital Management.
Will Gate Neurosciences IPO soon?
No public IPO plans have been announced for Gate Neurosciences.
How can I track Gate Neurosciences secondary market activity?
Caplight tracks bids, offers, and trades in Gate Neurosciences's shares on secondary markets.